Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Topical Tacrolimus 0,02% effect in a recurrent corneal infiltrate associated with ocular rosacea

Poster Details

First Author: A. Solans PĂ©rez de Larraya SPAIN

Co Author(s):    J. Ortega Molina   M. Gonzalez Gallardo   A. Salgado Miranda   I. Garcia del Moral           

Abstract Details


To report the clinical course of recurrent styes and corneal infiltrates occurring in a patient with ocular rosacea. To describe the effectiveness of oral doxyxycline and topical tacrolimus 0,02% emulsion in the treatment of the patient.


San Cecilio University Hospital, Spain


Observational case report.


A 21-year-old woman presented with flushing of the face, recurrent external styes, foreing-body sensation, photophobia in her right eye (OD). The symptoms had persisted for 6 months, with intermittent remissions. The best corrected visual acuity was 20/20 in the OD. Slit-lamp examination revealed telangiectasia with hyperemia of the eyelid margins, conjunctival hyperemia and superficial sectorial neovascularization of the cornea with corneal infiltrate. The patient had a partial response to 2 weeks with oral doxyxycline, topical fluorometolona and eyelid hygiene. Tacrolimus 0,02% was added, at 12 months of follow-up, the ocular hyperemia, the corneal infiltrate and the neovascularization had totally resolved.


An early diagnosis of rosacea and an adequate treatment is important to avoid ocular and skin morbidity. It is often undiagnosed and non specific diagnostic test is available. Oral treatment with doxycycline have been successfully used as an adjunct therapy to topical treatment. Tacrolimus 0,02% is a calcineurin inhibitors that reversibly inhibit T-cell proliferation and prevent the release of proinflammatory cytokines. It decreases inflammation within the eye and improves patient signs and symptoms. Topical tacrolimus 0,02% is better tolerated and has more corneal penetrance than Ciclosporina, it is an alternative treatment for long-term corneal ulcers.

Financial Disclosure:


Back to Poster listing